Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02077257
Recruitment Status : Unknown
Verified November 2014 by Committee of Cardio-Cerebral-Vascular Diseases of GSC.
Recruitment status was:  Recruiting
First Posted : March 4, 2014
Last Update Posted : November 7, 2014
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Committee of Cardio-Cerebral-Vascular Diseases of GSC

Brief Summary:

This is a 12-week, randomized, open-label,,multicenter, Phase IV study exploring LDL-C lowering efficacy of Rosuvastatin 20 mg/d compared to 10 mg/day Chinese ACS patients.The Randomized Treatment Period is preceded by a 24hours Screening Period. The study flow chart (Figure 1) depicts the 2 periods which comprise the study. These periods are described as follows:

  1. Screening Period (Day -1 through Day 1) This period consists of Visits 1 and 2. Subjects entering the Screening Period are required to meet the inclusion criteria. All subjects will be instructed to follow the current TLC(therapeutic lifestyle change)dietary guidelines for the duration of the trial.
  2. 12-week Randomized Treatment Period (Day 1 through Week 12) This period consists of Visits 2, 3, 4, and 5. Eligible subjects will be randomized at Visit 2 to each treatment group: Rosuvastatin 20 mg orRosuvastatin10 mg. Treatment will be administered once daily for 12 weeks.

A total of 450valid subjects in each of the Rosuvastatin arms are required, in order to test the hypothesis of superiority for comparison of LDL-C levels between Rosuvastatin20 mg and Rosuvastatin10 mg(see Section 6.1 for more details).

The Study visit schedule(Table 2) indicates the number and timing of the planned visits. The visit schedule must be within time window. At the final visit, it is the responsibility of the investigator to ensure the subject is offered an selected appropriate type of lipid-lowering therapy.

Scheduled Visit3,4,5 will have a visit window of ±2 days. Subjects who attend a clinic visit without fasting (at least 12 hours) should be asked to return within 2 days for another clinic visit after fasting for at least 12 hours.


Condition or disease Intervention/treatment Phase
Acute Coronary Syndrome Drug: Rosuvastatin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1060 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes
Study Start Date : March 2014
Estimated Primary Completion Date : December 2015
Estimated Study Completion Date : May 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Rosuvastatin 20mg
Rosuvastatin 20 mg/d
Drug: Rosuvastatin
Rosuvastatin 20 mg/d compared to 10 mg/day

Rosuvastatin 10mg
Rosuvastatin 10 mg/d
Drug: Rosuvastatin
Rosuvastatin 20 mg/d compared to 10 mg/day




Primary Outcome Measures :
  1. LDL-C absolute value and percent change from baseline [ Time Frame: 12 weeks ]
    Rosuvastatin 20mg/d ( absolute value and percent change from baseline) compared with that of Rosuvastatin 10mg/d (absolute value and percent change from baseline) in lowering LDL-C averaged over measurements at 12 weeks.


Secondary Outcome Measures :
  1. blood lipid goal achievement rate(LDL-C <70 mg/dl or 50% reduction) [ Time Frame: 6 week ]
    Efficacy of Rosuvastatin 20 mg/d vs Rosuvastatin 10 mg/don blood lipid goal achievement rate(LDL-C <70 mg/dl or 50% reduction) at Weeks 6

  2. blood lipid goal achievement rate(LDL-C <70 mg/dl or 50% reduction) [ Time Frame: 12 weeks ]
    Efficacy of Rosuvastatin 20 mg/d vs Rosuvastatin 10 mg/don blood lipid goal achievement rate(LDL-C <70 mg/dl or 50% reduction) at Weeks 12

  3. Percent change from baseline in TC,HDL-C, TG, nonHDL-C (non HDL-C = [TC-HDL-C]), ApoA-I, ApoB, LDL-C/HDL-C, TC/HDL-C, non HDL-C/HDL-C, ApoB/ApoA-I and LDL-C [ Time Frame: 6weeks ]
    Percent change from baseline in TC(total cholesterol), HDL-C(high density lipid cholesterol), TG(triglyceride), nonHDL-C (non HDL-C = [TC-HDL-C]), ApoA-I(apolipoprotein A ), ApoB(apolipoprotein B ), LDL-C/HDL-C, TC/HDL-C, non HDL-C/HDL-C, ApoB/ApoA-I and LDL-C at Weeks 6 .

  4. Percent change from baseline in TC, HDL-C, TG, nonHDL-C (non HDL-C = [TC-HDL-C]), ApoA-I, ApoB, LDL-C/HDL-C, TC/HDL-C, non HDL-C/HDL-C, ApoB/ApoA-I and LDL-C [ Time Frame: 12 weeks ]
    Percent change from baseline in TC, HDL-C, TG, nonHDL-C (non HDL-C = [TC-HDL-C]), ApoA-I, ApoB, LDL-C/HDL-C, TC/HDL-C, non HDL-C/HDL-C, ApoB/ApoA-I and LDL-C at week 12

  5. Percent change from baseline in the level of hsCRP(high-sensitivity C-reactive protein), an inflammatory marker [ Time Frame: 6 weeks ]
    Percent change from baseline in the level of hsCRP, an inflammatory marker, following 6 weeks

  6. Percent change from baseline in the level of hsCRP, an inflammatory marker, [ Time Frame: 12 weeks ]
    Percent change from baseline in the level of hsCRP, an inflammatory marker, following 12 weeks

  7. incidence and severity of adverse events [ Time Frame: 12 weeks ]
  8. abnormal physical examination findings [ Time Frame: 12 weeks ]
  9. abnormal laboratory values [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18-80 year old males and non-child-bearing period females.
  • Clinical diagnosed with acute coronary syndrome including NSTE-ACS ,MI and STEMI.
  • Patients with STEMI((ST segment elevation myocardial infarction) and NSTEMI(non-ST segment elevation myocardial infarction) will be recruited within 48 hours of symptom onset.
  • The LDL-C≥70mg/dL one week before randomization.
  • The TG<500mg/dL one week before randomization.
  • No cholesterol-lowering drugs (including lipid lowering dietary supplements, antioxidants, or food additives) during 4 weeks before randomization.
  • Sign the ICF(inform consent form)

Exclusion Criteria:

  • Acute pulmonary edema, severe congestive heart failure,
  • acute moderate mitral regurgitation, acute ventricular septal perforation,
  • severe arrhythmia (ventricular fibrillation, sustained ventricular tachycardia, complete heart block), sepsis, acute pericarditis,
  • any evidence of systemic or pulmonary embolus within the preceding 4 weeks.
  • Coronary artery bypass graft within the preceding 3 months; percutaneous coronary intervention within the preceding 6 months.
  • A history of hypersensitivity of statins and other severe complication.
  • child-bearing women
  • hypothyroidism,
  • active liver disease or dysfunction including agnogenic serum transaminase sustained elevation or higher than 3 times ULN(upper limit of normal)
  • severe anemia (hemoglobin,hematocrit < 28%),
  • Patients with myopathy or serum creatine kinase > 3 times the upper limit of normal not caused by myocardial injury.
  • A history of psychiatric disorders
  • A history of jejunoileal bypass or gastric bypass surgery
  • Currently take steroids therapy
  • Currently take phenytoin sodium,phenobarbital,carbamazepine (which may primary efficacy endpoint)
  • Diagnosed with malignant within 5 years
  • Severe renal function damage (creatinine clearance rate<30 ml/min)
  • Concurrent use ciclosporin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02077257


Contacts
Layout table for location contacts
Contact: Xubo Shi SHIXUBO@VIP.SINA.COM

Locations
Layout table for location information
China, Beijing
Beijing Anzhen Hospital Recruiting
Beijing, Beijing, China
Contact: Changsheng Ma, PhD         
Sponsors and Collaborators
Committee of Cardio-Cerebral-Vascular Diseases of GSC
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Dayi Hu, Doctor Beijing university People's hospital
Principal Investigator: Changsheng Ma, Doctor Beijing Anzhen Hospital

Layout table for additonal information
Responsible Party: Committee of Cardio-Cerebral-Vascular Diseases of GSC
ClinicalTrials.gov Identifier: NCT02077257    
Other Study ID Numbers: ROSE
First Posted: March 4, 2014    Key Record Dates
Last Update Posted: November 7, 2014
Last Verified: November 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Coronary Syndrome
Syndrome
Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors